Gore Introduces Excluder TAMBE Device in Europe

April 22, 2026—Gore & Associates announced that its Excluder thoracoabdominal branch endoprosthesis (TAMBE) received CE Mark approval earlier this year and is being introduced in hospitals across Europe.

The company advised that dedicated training programs have been developed to familiarize endovascular teams with the device’s capabilities. The Excluder TAMBE has been increasingly adopted in routine practice by numerous European vascular centers, noted Gore.

According to Gore, the TAMBE device is a complete, off-the-shelf endovascular solution for complex aneurysmal disease involving the visceral aorta. It is designed to address complexity in the repair of thoracoabdominal and pararenal aortic aneurysms.

It features a dedicated modular system for maximizing treatment flexibility while minimizing aortic coverage. Four integrated, precannulated internal portals allow for the placement of bridging stent grafts into visceral arteries. Also, an aortic component can be reconstrained, providing flexibility for precise positioning, noted the Gore press release.

Gore advised that the TAMBE pivotal study demonstrated the device’s safety and effectiveness at 1 year with at 100% freedom from lesion-related mortality, conversion, and migration; and 94% freedom from target vessel instability. The study’s 30-day findings included 99% freedom from disabling stroke and 98% freedom from paraplegia.

The 1-year data were presented at the 2025 Vascular Annual Meeting in New Orleans, Louisiana, with the abstract published by Mark A. Farber, MD et al in the Journal of Vascular Surgery (JVS; 2025;81:e236). The 30-day findings were published in November 2024 by Dr. Farber et al in JVS (2024;80;1326-1335).